Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.
|Original language||English (US)|
|Number of pages||5|
|Journal||Turkish Journal of Gastroenterology|
|State||Published - Nov 27 2000|
- Consensus interferon
- Hepatitis C
ASJC Scopus subject areas